Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1989-2-27
|
pubmed:abstractText |
We studied the sensitivity of human myeloma (plasma cell leukemia) toward autologous and allogeneic lymphokine-activated killer (LAK) cells. Fresh plasma cell leukemia (PCL)-derived peripheral blood mononuclear cells (PBMC) and PBMC from 3 normal donors were cultured in the presence of recombinant interleukin-2 (rIL2; 1,000 U/ml) for subsequent use as cytotoxic effectors against fresh and continuously cultured myeloma cells. Target cell lysis was measured in a 4-hour 51Cr radioisotope release assay. At an effector to target (E:T) ratio of 50:1, rIL2-induced PCL-PBMC lysed 48 +/- 19% (mean +/- 1 SD) of autologous myeloma targets, as compared to 89 +/- 5, 95 +/- 15, and 100 +/- 9% lysis of standard LAK-sensitive Daudi cells and allogeneic myeloma cell lines SKO-007, and RPMI-8226, respectively. Normal PBMC-derived rIL2-induced (LAK) cells exhibited a slightly lower cytotoxic reactivity against allogeneic targets (61 +/- 9, 60 +/- 6, and 81 +/- 8% cytolysis of SKO-007, RPMI-8226, and Daudi cells, respectively, at a 50:1 E:T ratio). Cytotoxicity against myeloma (PCL) of autologous PCL-derived killer cells could be significantly (at least 2-fold) enhanced when rIL-2-induced effector cells were preincubated for 18 h in the presence of recombinant Interferon-alpha rIFN-alpha; 1,000 U/ml). In summary, our results indicate the potential antitumor efficacy of rIL2- and rIL2 + rIFN-alpha-activated killer cells in human myeloma (PCL).
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0001-5792
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
80
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
203-9
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:3146198-Cells, Cultured,
pubmed-meshheading:3146198-Cytotoxicity, Immunologic,
pubmed-meshheading:3146198-Cytotoxicity Tests, Immunologic,
pubmed-meshheading:3146198-Humans,
pubmed-meshheading:3146198-Immunity, Cellular,
pubmed-meshheading:3146198-Interferon Type I,
pubmed-meshheading:3146198-Interferon-gamma,
pubmed-meshheading:3146198-Interleukin-2,
pubmed-meshheading:3146198-Killer Cells, Natural,
pubmed-meshheading:3146198-Lymphocyte Activation,
pubmed-meshheading:3146198-Multiple Myeloma,
pubmed-meshheading:3146198-Phenotype,
pubmed-meshheading:3146198-Recombinant Proteins
|
pubmed:year |
1988
|
pubmed:articleTitle |
Cell-mediated toxicity of interleukin-2-activated lymphocytes against autologous and allogeneic human myeloma cells.
|
pubmed:affiliation |
Laboratory of Hematopoietic Cell Kinetics and Hematology, Memorial Sloan-Kettering Cancer Center, New York.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|